Back to search results

A Study of ASC30 Tablets for Type 2 Diabetes

This study is testing an investigational medication called ASC30 tablets for people with Type 2 Diabetes Mellitus (T2DM). Researchers want to see how well ASC30 tablets work, if they are safe, and if people can tolerate them. You might be able to join if you are between 18 and 75 years old, have Type 2 Diabetes, and your HbA1c (a measure of blood sugar control) is between 7.0% and 10.5%. The main goal is to see how much ASC30 tablets can lower your HbA1c compared to a placebo (an inactive pill) over 13 weeks. The study is currently unclear on its recruitment status.

Study design
This is a randomized, double-blind, placebo-controlled Phase II study involving 100 participants. You would either receive ASC30 tablets or a placebo.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured up to 13 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07321678

A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus

Active, Not Recruiting
PHASE2Ages 18–75InterventionalTreatment
Ascletis Pharma (China) Co., Limited
~100 participants
Updated 2026-04-30 on ClinicalTrials.gov
What's tested:ASC30 tabletsPlacebo

At a glance

Recruiting sites
0 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean change from baseline in HbA1c up to 13 weeks in the treatment group compared with the placebo group
Measured over Baseline and end of Week 13

Conditions

T2DM (Type 2 Diabetes Mellitus)

Explore related trials

Type 2 Diabetes Mellitus

Where it's being run

8 sites across 6 states
California2
Florida2
Colorado1
Georgia1
Missouri1
Texas1

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have Type 2 Diabetes (T2D)
Have HbA1c ≥7.0% to ≤10.5% as determined by the central laboratory at screening.
Stable body weight (less than 5% self-reported change within the previous 3 months).
Have a BMI ≥23.0 kilogram/square meter (kg/m²) at screening.

Exclusion

Have any prior diagnosis of type 1 diabetes mellitus (T1DM), or rare forms of diabetes mellitus
Have had more than 1 episode of severe hypoglycemia
Have poorly controlled hypertension
Have acute or chronic hepatitis and pancreatitis
Have evidence of a significant active and uncontrolled medical condition

What this trial measures

  • Mean change from baseline in HbA1c up to 13 weeks in the treatment group compared with the placebo groupBaseline and end of Week 13